...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: 6%

"KBC, that would be the 6% Royalty steam paid to ZCC generated from the revenue that would come from successful ZEN-3694 in collaboration with BPs drugs. (vis-a-vis trials that are presently ongoing)"

 

yes i believe your correct koo - so if zen sold off zen-3694 would that mean we might see a little piece of that $$ with the majority of cash headed back to rvx? Plus would we still hold a chunk of all thats left or would we be shown the exit door at that point? This is my concern.

Share
New Message
Please login to post a reply